Wall Street brokerages expect Repligen Co. (NASDAQ:RGEN) to post earnings per share (EPS) of $0.22 for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Repligen’s earnings. The lowest EPS estimate is $0.19 and the highest is $0.24. Repligen posted earnings of $0.16 per share in the same quarter last year, which would suggest a positive year over year growth rate of 37.5%. The company is expected to report its next earnings report on Thursday, August 1st.

On average, analysts expect that Repligen will report full-year earnings of $0.93 per share for the current year, with EPS estimates ranging from $0.86 to $0.95. For the next financial year, analysts forecast that the business will report earnings of $1.12 per share, with EPS estimates ranging from $1.06 to $1.20. Zacks’ earnings per share averages are a mean average based on a survey of analysts that cover Repligen.

Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, May 9th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.02. Repligen had a return on equity of 6.35% and a net margin of 10.11%. The firm had revenue of $60.63 million during the quarter, compared to analyst estimates of $55.09 million. During the same quarter in the prior year, the company earned $0.17 EPS. The business’s revenue was up 35.3% compared to the same quarter last year.

Several research analysts have recently issued reports on RGEN shares. Zacks Investment Research raised Repligen from a “sell” rating to a “hold” rating in a research report on Wednesday, February 27th. ValuEngine lowered Repligen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 4th. Finally, BidaskClub lowered Repligen from a “hold” rating to a “sell” rating in a research report on Tuesday, April 9th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Repligen currently has a consensus rating of “Buy” and a consensus price target of $64.20.

Shares of NASDAQ:RGEN traded up $0.07 during trading on Thursday, hitting $81.98. The stock had a trading volume of 5,918 shares, compared to its average volume of 539,034. Repligen has a 12 month low of $45.00 and a 12 month high of $83.69. The company has a market cap of $3.87 billion, a P/E ratio of 112.25, a PEG ratio of 5.12 and a beta of 1.00. The company has a fifty day moving average of $72.43. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.18 and a quick ratio of 1.84.

In related news, Director Karen A. Dawes sold 1,295 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $77.35, for a total transaction of $100,168.25. Following the completion of the transaction, the director now owns 118,329 shares of the company’s stock, valued at approximately $9,152,748.15. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Glenn L. Md Cooper sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $66.94, for a total value of $334,700.00. Following the transaction, the director now directly owns 35,975 shares of the company’s stock, valued at approximately $2,408,166.50. The disclosure for this sale can be found here. 1.70% of the stock is owned by company insiders.

Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in shares of Repligen by 1.2% in the 1st quarter. BlackRock Inc. now owns 5,650,666 shares of the biotechnology company’s stock worth $333,841,000 after buying an additional 66,580 shares during the last quarter. Conestoga Capital Advisors LLC raised its holdings in Repligen by 1.3% during the first quarter. Conestoga Capital Advisors LLC now owns 1,637,430 shares of the biotechnology company’s stock valued at $96,739,000 after acquiring an additional 21,393 shares during the period. OppenheimerFunds Inc. raised its holdings in Repligen by 9.0% during the first quarter. OppenheimerFunds Inc. now owns 1,082,943 shares of the biotechnology company’s stock valued at $63,980,000 after acquiring an additional 89,226 shares during the period. Federated Investors Inc. PA raised its holdings in Repligen by 0.9% during the first quarter. Federated Investors Inc. PA now owns 950,414 shares of the biotechnology company’s stock valued at $56,150,000 after acquiring an additional 8,641 shares during the period. Finally, Lord Abbett & CO. LLC raised its holdings in Repligen by 286.3% during the fourth quarter. Lord Abbett & CO. LLC now owns 733,291 shares of the biotechnology company’s stock valued at $38,674,000 after acquiring an additional 543,443 shares during the period. 84.90% of the stock is owned by institutional investors.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

See Also: How does a security become overbought?

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.